As the crisis in anti-infective medicine resistance draws closer, the fundamental problems with the existing model for incentivisation of antibiotic research grow ever clearer. Are there issues here with relevance for drug repurposing R&D?
As the crisis in anti-infective medicine resistance draws closer, the fundamental problems with the existing model for incentivisation of antibiotic research grow ever clearer. Are there issues here with relevance for drug repurposing R&D?